AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32616309 — intervention group
Group type: EXPERIMENTAL
Intervention: All anaesthetics with lidocaine
Number of subjects: 120
Study 32616309 — intervention group
Group type: COMPARATOR
Intervention: All anaesthetics without lidocaine
Number of subjects: 120
Study 32616309 — intervention group
Group type: EXPERIMENTAL
Intervention: All anaesthetics
Number of subjects: 120
Study 36167484 — intervention group
Group type: COMPARATOR
Intervention: Single Vision Spectacle Lenses (SVL)
Number of subjects: 170
Study 36167484 — intervention group
Group type: EXPERIMENTAL
Intervention: Slightly Aspherical Lenslets (SAL)
Number of subjects: 170
Study 36167484 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly Aspherical Lenslets (HAL)
Number of subjects: 170
Study 34024502 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES (Neuromuscular electrical stimulation) applied bilaterally at the origin and insertion points of the quadriceps or gastrocnemius muscles for 40 min during each HD session (3x/wk for one month)
Number of subjects: 21
Study 34024502 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 21
Study 36419027 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth plan group
Number of subjects: 106
Study 33321008 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-page visual illustration (group I)
Number of subjects: 152
Study 33321008 — intervention group
Group type: COMPARATOR
Intervention: Usual text consent brochure (group II)
Number of subjects: 152
Study 33308348 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (n=37)
Number of subjects: 77
Study 33308348 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=40)
Number of subjects: 77
Study 34637848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive community-based intervention (weekly group activities including physical activity and education)
Number of subjects: 67
Study 34637848 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 67
Study 36401471 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiehuangjiejing (XHJJ) granule, 4.5 g administered 3 times daily
Number of subjects: 180
Study 36401471 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo, 4.5 g administered 3 times daily
Number of subjects: 180
Study 34567439 — intervention group
Group type: COMPARATOR
Intervention: EMDR
Number of subjects: 62
Study 34567439 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR 2.0
Number of subjects: 62
Study 35998864 — intervention group
Group type: EXPERIMENTAL
Intervention: TX Sprouts intervention (gardening, nutrition, and cooking program)
Number of subjects: 16
Study 35998864 — intervention group
Group type: COMPARATOR
Intervention: Control (delayed intervention)
Number of subjects: 16
Study 33960277 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg daily for three months)
Number of subjects: 90
Study 33960277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 32380445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta-burst stimulation (iTBS)
Number of subjects: 57
Study 32380445 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 57
Study 35785139 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 140
Study 35785139 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 140
Study 32707476 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsible Marijuana Vendor (RMV) training
Number of subjects: 150
Study 32707476 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RMV training)
Number of subjects: 150
Study 32707476 — intervention group
Group type: EXPERIMENTAL
Intervention: Stores using RMV training
Number of subjects: 150
Study 32707476 — intervention group
Group type: COMPARATOR
Intervention: Stores not using RMV training
Number of subjects: 150
Study 34056699 — intervention group
Group type: EXPERIMENTAL
Intervention: CAB + RPV LA Q8W
Number of subjects: 1045
Study 34056699 — intervention group
Group type: COMPARATOR
Intervention: CAB + RPV LA Q4W
Number of subjects: 1045
Study 32810030 — intervention group
Group type: EXPERIMENTAL
Intervention: One-anastomosis gastric bypass (OAGB)
Number of subjects: 40
Study 32810030 — intervention group
Group type: COMPARATOR
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 40
Study 32962531 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly patients with cancer
Number of subjects: 123
Study 32962531 — intervention group
Group type: COMPARATOR
Intervention: Elderly patients with depression
Number of subjects: 123
Study 32962531 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patients with cancer
Number of subjects: 123
Study 32962531 — intervention group
Group type: COMPARATOR
Intervention: Younger patients with depression
Number of subjects: 123
Study 33119423 — intervention group
Group type: EXPERIMENTAL
Intervention: lemborexant 5 mg/day
Number of subjects: 9
Study 33119423 — intervention group
Group type: EXPERIMENTAL
Intervention: lemborexant 10 mg/day
Number of subjects: 9
Study 33119423 — intervention group
Group type: EXPERIMENTAL
Intervention: lemborexant (5 mg/day or 10 mg/day)
Number of subjects: 9
Study 33119423 — intervention group
Group type: EXPERIMENTAL
Intervention: lemborexant
Number of subjects: 9
Study 33119423 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 33119423 — intervention group
Group type: COMPARATOR
Intervention: zolpidem
Number of subjects: 9
Study 33119423 — intervention group
Group type: COMPARATOR
Intervention: zopiclone
Number of subjects: 9
Study 33306634 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg effervescent tablets, three tablets per day for two days prior to RNT)
Number of subjects: 34
Study 33306634 — intervention group
Group type: COMPARATOR
Intervention: Routine RNT without any intervention (Control group)
Number of subjects: 34
Study 33025021 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Based Participatory Research (CBPR) intervention for unhealthy alcohol use
Number of subjects: 121
Study 35791020 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART, a 6-week transdiagnostic CBT for anxiety and depression
Number of subjects: 163
Study 35791020 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (WLC)
Number of subjects: 163
Study 33706868 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet reactivity-based strategy (daily measurements of platelet reactivity by Multiplate analyzer)
Number of subjects: 190
Study 33706868 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (P2Y12 receptor inhibitor withdrawn 5 to 7 days before CABG)
Number of subjects: 190
Study 33355676 — intervention group
Group type: EXPERIMENTAL
Intervention: Burnout measured with the Maslach Burnout Inventory (MBI)
Number of subjects: 715
Study 33355676 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression measured with the Hospital Depression and Anxiety Scale (HADS)
Number of subjects: 715
Study 33355676 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety measured with the Hospital Depression and Anxiety Scale (HADS)
Number of subjects: 715
Study 33355676 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmatory factor analyses
Number of subjects: 715
Study 33355676 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory graph analysis combining gaussian graphical model with clustering algorithms
Number of subjects: 715
Study 33355676 — intervention group
Group type: EXPERIMENTAL
Intervention: Key indicators for screening instruments
Number of subjects: 715
Study 34545997 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (CLS) 50 mg twice daily plus escitalopram (ESC) 20 mg once daily for six weeks
Number of subjects: 80
Study 34545997 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus escitalopram (ESC) 20 mg once daily for six weeks
Number of subjects: 80
Study 32085838 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate (YKP3089)
Number of subjects: 0
Study 32085838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34162993 — intervention group
Group type: EXPERIMENTAL
Intervention: tACS at β frequency (20 Hz) with rPPS
Number of subjects: 0
Study 34162993 — intervention group
Group type: COMPARATOR
Intervention: Sham tACS with rPPS
Number of subjects: 0
Study 34162993 — intervention group
Group type: EXPERIMENTAL
Intervention: tACS at α frequency (10 Hz) with rPPS
Number of subjects: 0
Study 34162993 — intervention group
Group type: EXPERIMENTAL
Intervention: tACS at β frequency (20 Hz) in trough phase with rPPS
Number of subjects: 0
Study 32481584 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% P-CM
Number of subjects: 0
Study 32481584 — intervention group
Group type: COMPARATOR
Intervention: CM
Number of subjects: 0
Study 34973597 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate (1500 mg, twice daily for 4 days)
Number of subjects: 22
Study 34973597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 33188988 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 92
Study 33188988 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (Control)
Number of subjects: 92
Study 32133585 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tyrosine (2.0 g)
Number of subjects: 45
Study 32133585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 36484666 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral scanning
Number of subjects: 70
Study 36484666 — intervention group
Group type: COMPARATOR
Intervention: Conventional impression-taking
Number of subjects: 70
Study 33690706 — intervention group
Group type: EXPERIMENTAL
Intervention: Model incorporating time‐varying smoking variables
Number of subjects: 126528
Study 33690706 — intervention group
Group type: COMPARATOR
Intervention: Pack-years model
Number of subjects: 126528
Study 36078292 — intervention group
Group type: EXPERIMENTAL
Intervention: Mat Pilates (MP)
Number of subjects: 60
Study 36078292 — intervention group
Group type: EXPERIMENTAL
Intervention: Mat Pilates + Aerobic Exercise (MP+AE)
Number of subjects: 60
Study 36078292 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no exercises)
Number of subjects: 60
Study 34570072 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive Spirometry (IS) - 10 deep breaths with a spirometer every 2 hours starting 2 hours after surgery
Number of subjects: 84
Study 34570072 — intervention group
Group type: COMPARATOR
Intervention: Control group (no respiratory physiotherapy)
Number of subjects: 84
Study 35722980 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion training provided to elderly individuals, one session a week for three weeks
Number of subjects: 140
Study 35722980 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 140
Study 32552857 — intervention group
Group type: EXPERIMENTAL
Intervention: OPTIMIZE intervention
Number of subjects: 2400
Study 32552857 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 2400
Study 34422261 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programme plus food education sessions (EXFE)
Number of subjects: 33
Study 34422261 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercise programme (EX)
Number of subjects: 33
Study 32602301 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 80
Study 32602301 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 80
Study 35738184 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdiscectomy
Number of subjects: 122
Study 35165477 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioceramic putty repairmen iRoot
Number of subjects: 43
Study 35165477 — intervention group
Group type: COMPARATOR
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 43
Study 34967382 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency therapy
Number of subjects: 86
Study 34967382 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 86
Study 35056367 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 24
Study 35056367 — intervention group
Group type: COMPARATOR
Intervention: Education intervention
Number of subjects: 24
Study 35038278 — intervention group
Group type: EXPERIMENTAL
Intervention: Children accompanied by anxious parents
Number of subjects: 160
Study 35038278 — intervention group
Group type: COMPARATOR
Intervention: Children accompanied by non-anxious parents
Number of subjects: 160
Study 35038278 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with parents present
Number of subjects: 160
Study 35038278 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with anxious parents
Number of subjects: 160
Study 34589205 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency tart cherries (MC) 30 ml twice daily for 28 days
Number of subjects: 23
Study 34589205 — intervention group
Group type: COMPARATOR
Intervention: Placebo 30 ml twice daily for 28 days
Number of subjects: 23
Study 34589205 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency tart cherries (MC)
Number of subjects: 23
Study 34589205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 33879224 — intervention group
Group type: EXPERIMENTAL
Intervention: IY‐ASLD program
Number of subjects: 70
Study 33879224 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 70
Study 33377701 — intervention group
Group type: EXPERIMENTAL
Intervention: 180W front-firing GreenLight laser PVP
Number of subjects: 61
Study 33377701 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 61
Study 35988825 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 international units)
Number of subjects: 107
Study 35988825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 33935265 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week summer nursing immersion program at a graduate school of nursing
Number of subjects: 3
Study 32223116 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation plus clopidogrel
Number of subjects: 313
Study 32223116 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulation alone
Number of subjects: 313
Study 33291088 — intervention group
Group type: EXPERIMENTAL
Intervention: CA2122
Number of subjects: 244
Study 33291088 — intervention group
Group type: COMPARATOR
Intervention: VERO
Number of subjects: 244
Study 32068870 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone (0.75-6 mg, dosing interval 0.75 mg)
Number of subjects: 27
Study 32068870 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone
Number of subjects: 27
Study 34211322 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance band exercise training (EX) 3 days/week
Number of subjects: 35
Study 34211322 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 35
Study 35459947 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid Binding sperm Selection (HABSelect)
Number of subjects: 2752
Study 35459947 — intervention group
Group type: COMPARATOR
Intervention: Physiological IntraCytoplasmic Sperm Injection (PICSI)
Number of subjects: 2752
Study 32749916 — intervention group
Group type: COMPARATOR
Intervention: Ratio 1:2
Number of subjects: 44
Study 32749916 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio 1:1.2
Number of subjects: 44
Study 32281648 — intervention group
Group type: EXPERIMENTAL
Intervention: P < .05
Number of subjects: 0
Study 32281648 — intervention group
Group type: EXPERIMENTAL
Intervention: P < .005
Number of subjects: 0
Study 32281648 — intervention group
Group type: EXPERIMENTAL
Intervention: P < .20
Number of subjects: 0
Study 32281648 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher threshold (e.g., P < .2)
Number of subjects: 0
Study 32281648 — intervention group
Group type: COMPARATOR
Intervention: 0.05 threshold
Number of subjects: 0
Study 35731517 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily
Number of subjects: 6564
Study 35731517 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus aspirin 100 mg daily
Number of subjects: 6564
Study 32950650 — intervention group
Group type: EXPERIMENTAL
Intervention: p factor at baseline
Number of subjects: 0
Study 32590944 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary prourokinase (10 ml)
Number of subjects: 50
Study 32590944 — intervention group
Group type: COMPARATOR
Intervention: Control (10 ml saline)
Number of subjects: 50
Study 34255088 — intervention group
Group type: EXPERIMENTAL
Intervention: Training workshop (TRANSLATE) for Implementation Leads
Number of subjects: 9
Study 34313728 — intervention group
Group type: EXPERIMENTAL
Intervention: Malkia Klabu loyalty programme
Number of subjects: 0
Study 34647981 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib treatment
Number of subjects: 1052
Study 32513163 — intervention group
Group type: EXPERIMENTAL
Intervention: GENIE social network self-management intervention
Number of subjects: 0
Study 32513163 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 36335403 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified muscle sparing technique (SPAIRE) in hip hemiarthroplasty
Number of subjects: 0
Study 36335403 — intervention group
Group type: COMPARATOR
Intervention: Standard lateral technique in hip hemiarthroplasty
Number of subjects: 0
Study 34277985 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 35
Study 34277985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 35977778 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal hydromorphone (100 μg)
Number of subjects: 126
Study 35977778 — intervention group
Group type: COMPARATOR
Intervention: No block (Control)
Number of subjects: 126
Study 34125700 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-led total sanitation (CLTS) intervention
Number of subjects: 906
Study 33013880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 33013880 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g TXA
Number of subjects: 149
Study 33013880 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g TXA
Number of subjects: 149
Study 34159757 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg fidgeting during prolonged sitting
Number of subjects: 20
Study 33611573 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer survivors (breast cancer)
Number of subjects: 14316
Study 33611573 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer survivors (leukemia)
Number of subjects: 14316
Study 33611573 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer survivors (Hodgkin lymphoma)
Number of subjects: 14316
Study 33611573 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer survivors (non-Hodgkin lymphoma)
Number of subjects: 14316
Study 33611573 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer survivors (thyroid cancer)
Number of subjects: 14316
Study 33611573 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer survivors (melanoma)
Number of subjects: 14316
Study 33611573 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer survivors (overall)
Number of subjects: 14316
Study 33611573 — intervention group
Group type: COMPARATOR
Intervention: Unexposed women
Number of subjects: 14316
Study 32164314 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Circuit Training (HIICT)
Number of subjects: 54
Study 32164314 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 54
Study 35834738 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training with virtual reality
Number of subjects: 31
Study 35834738 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training alone
Number of subjects: 31
Study 35834738 — intervention group
Group type: COMPARATOR
Intervention: Standard of care overground therapy
Number of subjects: 31
Study 33516712 — intervention group
Group type: EXPERIMENTAL
Intervention: DTA (DiamondTemp Ablation System)
Number of subjects: 482
Study 33516712 — intervention group
Group type: COMPARATOR
Intervention: Control (force-sensing RF ablation system)
Number of subjects: 482
Study 32419536 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab
Number of subjects: 126
Study 32419536 — intervention group
Group type: COMPARATOR
Intervention: adalimumab
Number of subjects: 126
Study 32419536 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 126
Study 34275259 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 12
Study 34275259 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Exercise (MICE)
Number of subjects: 12
Study 34275259 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 12
Study 33336698 — intervention group
Group type: EXPERIMENTAL
Intervention: DOR/3TC/TDF (Doravirine 100 mg, Lamivudine 300 mg, Tenofovir Disoproxil Fumarate 300 mg)
Number of subjects: 734
Study 33336698 — intervention group
Group type: COMPARATOR
Intervention: EFV/FTC/TDF (Efavirenz 600 mg, Emtricitabine 200 mg, Tenofovir Disoproxil Fumarate 300 mg)
Number of subjects: 734
Study 33336698 — intervention group
Group type: EXPERIMENTAL
Intervention: DOR/3TC/TDF
Number of subjects: 734
Study 33336698 — intervention group
Group type: COMPARATOR
Intervention: EFV/FTC/TDF
Number of subjects: 734
Study 32574384 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-neutral vaccination
Number of subjects: 8022
Study 32574384 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls-only vaccination
Number of subjects: 8022
Study 36209076 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-peer facilitators
Number of subjects: 365
Study 36209076 — intervention group
Group type: COMPARATOR
Intervention: Faculty facilitators
Number of subjects: 365
Study 33817809 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive phototherapy protocol ('Perio‐1') with root surface debridement (RSD)
Number of subjects: 60
Study 33817809 — intervention group
Group type: COMPARATOR
Intervention: Root surface debridement (RSD) alone (control sextants)
Number of subjects: 60
Study 33817809 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive phototherapy protocol ('Perio‐1') with RSD
Number of subjects: 60